584222

Tetrahydrouridine

Potent competitive inhibitor of cytidine deaminase. Also available as a 100 mM solution in H2O.

• Sinónimos: Tetrahydrouridine
• Fórmula empírica (notación de Hill): C₉H₁₆N₂O₆
• Número de CAS: 18771-50-1
• Peso molecular: 248.23
• UNSPSC Code: 12352208

Propiedades

• Quality Level: 100
• assay: ≥90% (TLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; desiccated (hygroscopic); protect from light
• color: white to off-white
• solubility: water: 200 mg/mL
• shipped in: wet ice
• storage temp.: −20°C
• InChI: 1S/C9H16N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h4-8,12-15H,1-3H2,(H,10,16)/t4-,5?,6-,7-,8-/m1/s1
• InChI key: UCKYOOZPSJFJIZ-XVKVHKPRSA-N

Descripción

General description

A potent competitive inhibitor of cytidine deaminase. Used in combination with cytosine arabinoside (Ara-C) to assess the anti-leukemic activity and anti-tumor activity of Ara-C in in vitro studies.

Potent competitive inhibitor of cytidine deaminase. Also available as a 100 mM solution in H₂O(Cat. No. 584223).

Application

• Oncotherapy resistance explained by Darwinian and Lamarckian models.: This research explores the mechanisms of oncotherapy resistance, combining Darwinian and Lamarckian models to provide a comprehensive understanding. The study highlights the role of Tetrahydrouridine in modulating therapy resistance pathways in cancer treatment (Saunthararajah et al., 2024).


• Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.: This study investigates the potential of using Tetrahydrouridine in non-cytotoxic therapies for small cell lung cancers, focusing on neuroendocrine lineage commitment and its implications for treatment efficacy (Biswas et al., 2023).


• In Vitro Interaction of Tetrahydrouridine with Key Human Nucleoside Transporters.: This study explores how Tetrahydrouridine interacts with human nucleoside transporters, shedding light on its mechanisms of action and potential as a therapeutic agent in biochemistry and pharmacology (Säll et al., 2023).


• Mycoplasma infection of cancer cells enhances anti-tumor effect of oxidized methylcytidines.: This research investigates how mycoplasma infection enhances the anti-tumor effects of oxidized methylcytidines, with Tetrahydrouridine playing a crucial role in the observed therapeutic outcomes (Pang et al., 2023).

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot, purge with inert gas, and freeze (-20°C). Aqueous stock solutions (at neutral or basic pH) are stable for up to 3 months at -20°C.

Other Notes

Yusa, K., et al. 1995. Biochem. Biophys. Res. Commun. 206, 486.
Bouffard, D.Y., et al. 1993. Biochem Pharmacol.45, 1857.
Laliberte, J., et al. 1992. Cancer Chemotherap. Pharmacol.30, 7.
Riva, C., et al. 1992. Chemotherapy38, 358.
Yusa, K., et al. 1992. J. Biol. Chem. 267, 16848.
Hanze, A.R. 1967. J. Am. Chem. Soc.89, 6720.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable